HomeCompareELOX vs EQR

ELOX vs EQR: Dividend Comparison 2026

ELOX yields 2475.25% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ELOX wins by $73382614261.74M in total portfolio value
10 years
ELOX
ELOX
● Live price
2475.25%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$73382614261.78M
Annual income
$67,980,042,160,694,380.00
Full ELOX calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — ELOX vs EQR

📍 ELOX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodELOXEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ELOX + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ELOX pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ELOX
Annual income on $10K today (after 15% tax)
$210,396.04/yr
After 10yr DRIP, annual income (after tax)
$57,783,035,836,590,220.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, ELOX beats the other by $57,783,035,836,586,980.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ELOX + EQR for your $10,000?

ELOX: 50%EQR: 50%
100% EQR50/50100% ELOX
Portfolio after 10yr
$36691307130.91M
Annual income
$33,990,021,080,349,100.00/yr
Blended yield
92.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

ELOX
Analyst Ratings
8
Buy
3
Hold
Consensus: Buy
Altman Z
-94.4
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ELOX buys
0
EQR buys
0
No recent congressional trades found for ELOX or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricELOXEQR
Forward yield2475.25%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$73382614261.78M$40.5K
Annual income after 10y$67,980,042,160,694,380.00$3,819.61
Total dividends collected$73004868605.64M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: ELOX vs EQR ($10,000, DRIP)

YearELOX PortfolioELOX Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$258,225$247,524.75$11,248$547.57+$247.0KELOX
2$6,249,854$5,973,553.08$12,701$666.53+$6.24MELOX
3$141,807,743$135,120,399.71$14,405$814.59+$141.79MELOX
4$3,017,015,462$2,865,281,177.24$16,413$999.84+$3017.00MELOX
5$60,200,153,348$56,971,946,803.11$18,795$1,232.92+$60200.13MELOX
6$1,126,836,870,511$1,062,422,706,429.18$21,639$1,527.95+$1126836.85MELOX
7$19,791,333,921,123$18,585,618,469,676.22$25,057$1,903.80+$19791333.90MELOX
8$326,252,175,090,930$305,075,447,795,328.50$29,197$2,385.87+$326252175.06MELOX
9$5,049,132,804,749,982$4,700,042,977,402,686.00$34,250$3,008.70+$5049132804.72MELOX
10$73,382,614,261,776,860$67,980,042,160,694,380.00$40,467$3,819.61+$73382614261.74MELOX

ELOX vs EQR: Complete Analysis 2026

ELOXStock

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

Full ELOX Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this ELOX vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ELOX vs SCHDELOX vs JEPIELOX vs OELOX vs KOELOX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.